Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$126.17 USD

126.17
312,945

+1.92 (1.55%)

Updated Sep 12, 2024 04:00 PM ET

After-Market: $126.25 +0.08 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction

PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Masimo's (MASI) R&D activities raise optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?

Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.

Veeva Systems (VEEV) Offerings Adopted by SK Life Science

Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.

Stryker's (SYK) New Tech Aims to Improve Surgeon's Efficiency

Stryker's (SYK) Blueprint Mixed Reality Guidance system aims to benefit shoulder arthroplasty surgeons by improving efficiency and minimizing errors.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand

Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.

Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?

Integer (ITGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand

Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.

Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y

Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.

Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues

Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.

GE Healthcare (GEHC) Buys MIM Software to Boost Imaging Tools

GE Healthcare (GEHC) is likely to enhance medical imaging capabilities and boost powerful AI solutions with the acquisition of MIM Software. Financial details are kept under cover.

Veradigm (MDRX) & MedAllies Partner for Better Care Decisions

Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.

Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

SenesTech's (SNES) New Partnership to Broaden Evolve's Scope

The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.

PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues

Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.

DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.

Fresenius Medical (FMS) Divests Businesses to Optimize Portfolio

Fresenius Medical (FMS) streamlines for success with three key divestments in 2023. These divestments are likely to impact operating income by EUR 500 million in the fourth quarter.

Illumina (ILMN) Extends Partnership to Advance Cancer Test

Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales

Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.